Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second ...

Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the ...

Information About Us Contact us Feedback Terms Of Service Privacy Policy Subscriber Agreement JPost Jobs Cancel Subscription Sitemap Customer Service JP Store ...

Shares soared after pharma giant Novo Nordisk announced it will distribute its blockbuster GLP-1 weight loss drug Wegovy through telehealth platforms like Hims & Hers and LifeMD. Novo Nordisk ...

The Danish drugmaker is racing to capture more patients now that many compounding pharmacies are legally restricted from making cheaper, unapproved versions of Wegovy, with rare exceptions.

Shares of online pharmacy Hims & Hers surged after it struck a deal with Danish obesity drug maker Novo Nordisk to sell its Wegovy drug in the U.S. In a joint venture with Novo Nordisk ...

This new offering will be available through NovoCare® Pharmacy, allowing patients to directly access all FDA-approved dose strengths of Wegovy® via LifeMD’s virtual care platform. LifeMD’s ...

That partnership will see Hims & Hers offer Novo Nordisk’s weight-loss drug Wegovy through its platform. Here’s what you need to know. Hims & Hers will offer weight-loss drug Wegovy Hims ...

The maker of Wegovy is making the GLP1 medication available to several telehealth companies. Donald Trump Hit by Triple Legal Setback Within Hours See the first new dire wolf cubs born in over ...